PALMOPLANTAR PUSTULOSIS
Clinical trials for PALMOPLANTAR PUSTULOSIS explained in plain language.
Never miss a new study
Get alerted when new PALMOPLANTAR PUSTULOSIS trials appear
Sign up with your email to follow new studies for PALMOPLANTAR PUSTULOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising drug for hand and foot blisters falls short in early trial
Disease control TerminatedThis study tested a daily pill called deucravacitinib in 3 adults with palmoplantar pustulosis (PPP), a painful skin condition causing blisters on palms and soles. The goal was to see if the drug could reduce disease severity by at least 50% over 24 weeks. However, the trial was …
Matched conditions: PALMOPLANTAR PUSTULOSIS
Phase: PHASE4 • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug hope for painful hand and foot pustules
Disease control TerminatedThis trial tested the drug deucravacitinib in people with moderate-to-severe palmoplantar pustulosis, a skin condition causing painful pustules on the palms and soles. The study planned to enroll 25 participants who would take the drug daily for 16 weeks, but it was terminated ea…
Matched conditions: PALMOPLANTAR PUSTULOSIS
Phase: NA • Sponsor: Peking University First Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Spesolimab shows promise for Long-Term control of painful hand and foot pustules
Disease control TerminatedThis study looks at the long-term safety of spesolimab for people with palmoplantar pustulosis, a chronic skin condition causing painful pustules on hands and feet. Participants who benefited from spesolimab in earlier trials can continue treatment for up to 5 years, with monthly…
Matched conditions: PALMOPLANTAR PUSTULOSIS
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC